Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
---|---|---|---|---|---|---|
Bayer | Aflibercept | Eylea |  | 2012-11-21 |  |  |
Biocon | Aflibercept | Yesafili |  | 2024-05-20 |  |  |
Genentech | Ranibizumab | Lucentis |  | 2006-06-30 |  |  |
Ranibizumab | Susvimo |  | 2021-10-22 |  |  | |
Faricimab | Vabysmo |  | 2022-01-28 |  |  | |
Midas Pharma | Ranibizumab | Ranivisio |  | 2022-08-25 |  |  |
Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,722 M | Q2/21-Q2/24 |
Regeneron Pharmaceuticals | Aflibercept | Eylea |  | 2011-11-18 | $5,217.8 M | Q3/23-Q2/24 |
Roche | Faricimab | Vabysmo |  | 2022-09-15 | $2,221.9 M | Q4/22-Q3/23 |
Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-09-17 |  |  |
Sandoz | Ranibizumab | Cimerli |  | 2022-08-02 |  |  |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
---|---|---|---|---|---|